News

Some 12 million Burkinabè aged between 1 and 29 years of age are currently receiving MenAfriVac

First call for applications is open. You can now apply for access to the TRANSVAC infrastructure services. Deadline 31 January 2011.

The new page listing vaccinology course has been created as a help to our partners and collaborators etc.

The EC-funded, EVI coordinated project PHARVAT now has its own web site.

Dr. Chetan Chitnis, inventor of the EVI supported JAIVAC-1 malaria vaccine project, has received an Infosys award

European stakeholders of vaccine research and development convened in Brussels yesterday. A private-public working group starts to prepare concrete proposals to strengthen Europe’s vaccine infrastructure.

The first vaccinations of the candidate malaria vaccine, JAIVAC-1, with Montanide ISA 720 VG as adjuvant, have been administered to the first group of volunteers in India.

Safety and immunogenicity of heterologous prime‐boost with the candidate malaria vaccines ChAd63 ME‐TRAP and MVA ME‐TRAP in healthy adults in East and West Africa

Heidelberg/Lelystad, July 2010 - European Vaccine Initiative (EVI, previously known as European Malaria Vaccine Initiative) and TuBerculosis Vaccine Initiative (TBVI) recently signed a Memorandum of Understanding (MoU) for enhanced collaboration